Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]
Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R. Int J Nanomedicine. 2017;12:8025–8034.On page 8025, the first affiliation was listed as “Department of Pediatrics, Union Hospital, Tongji Medical College, University of Science and Technology, Wuhan” however it should have been...
Guardado en:
Autores principales: | Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c87834b03b324e4780656bb26a09f54b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
por: Wu X, et al.
Publicado: (2017) -
Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]
por: Soosay Raj TA, et al.
Publicado: (2013) -
OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
por: David Wroblewski, et al.
Publicado: (2013) -
ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
por: Huan Wang, et al.
Publicado: (2012) -
Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
por: Thomas X
Publicado: (2012)